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Mild cognitive impairment: animal models
Giancarlo Pepeu, MD
Mild cognitive impairment (MCI) is an aspect of cogni-
tive aging that is considered to be a transitional state
between normal aging and the dementia into which it
may convert. Appropriate animal models are necessary
in order to understand the pathogenic mechanisms of
MCI and develop drugs for its treatment. In this review,
we identify the features that should characterize an ani-
mal model of MCI, namely old age, subtle memory
impairment, mild neuropathological changes, and
changes in the cholinergic system, and the age at which
these features can be detected in laboratory animals.
These features should occur in aging animals with nor-
mal motor activity and feeding behavior. The animal
models may be middle-aged rats and mice, rats with
brain ischemia, transgenic mice overexpressing amyloid
precursor protein and presenilin 1 (tested at an early
stage), or aging monkeys. Memory deficits can be
detected by selecting appropriately difficult behavioral
tasks, and the deficits can be associated with neu-
ropathological alterations. The reviewed literature
demonstrates that, under certain conditions, these ani-
mal species can be considered to be MCI models, and
that cognitive impairment in these models responds to
drug treatment.  
© 2004, LLS SAS Dialogues Clin Neurosci. 2004;6:369-377.
n the basis of the descriptions presented else-
where in this issue,it is clear that it is difficult to identify
or develop an animal model reproducing most,if not all,
the features of human mild cognitive impairment (MCI).
To begin with,an animal cannot complain about mem-
ory, and it is difficult to assess whether its daily life is
affected. However, correspondence between animal
models and human pathology is only partial in all neu-
rodegenerative diseases including Alzheimer’s disease
(AD) and Parkinson’s disease.Nevertheless,even if they
only partially reproduce the disease,animal models are
quite useful for at least two purposes:understanding the
pathogenic mechanisms of a disease; and testing the
activity of new drugs to assess their potential activity
prior to clinical trials.
General features of MCI animal models
If the purpose is to understand pathogenic mechanisms,
the animal model should mimic as closely as possible the
symptoms,neuropathology,and mechanisms of the dis-
ease. Conversely, if the purpose is to demonstrate the
potential efficacy of a drug,the animal model could be
less complex,but should be easily available in large quan-
tities and reasonably priced.
On the basis of the clinical description of MCI and other
considerations, the ideal features of an MCI animal
model are listed in Table I.The number of these features
actually present in the models may vary according to the
animal species used.Cerebrovascular alterations should
be present only in models reproducing MCI occurring in
patients affected by cerebrovascular diseases.
1
In attempting to identify MCI animal models,the prob-
lem arises of how to distinguish them from AD animal
models.This problem parallels the situation facing the
clinician having to distinguish between MCI and the ini-
O
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tial stages of AD.
2 Since a characteristic of AD is the
degeneration of forebrain cholinergic neurons, animal
models of AD were obtained by destroying the forebrain
cholinergic nuclei,namely the nucleus basalis,
3 in the rat
through the use of neurotoxins.
Rats with small lesions in the nucleus basalis show only
limited cognitive impairment associated with a modest
cholinergic deficit and present at least two of the features
listed in Table I,namely subtle memory impairment and
mild neuropathological lesions.They could reasonably be
considered a model of MCI or of the prodromal phase in
AD. In an extensive review of animal models of the
mnemonic impairment in AD,McDonald and Overmier
4
conclude that those with a lesion in the medial septal
nucleus show behavioral deficits that are most similar to
the memory impairment observed in the earliest stage of
AD.Transgenic mice overexpressing β-amyloid (Aβ) and
presenilin 1,and aging animals in general,including aging
monkeys, are commonly used as animal models in AD
research.In all these models,the discriminating criteria
between MCI and AD models are the severity of dam-
age induced by the lesions, and the age at onset and
severity of the cognitive impairment in the rats,monkeys,
and transgenic mice under study.
Memory loss complaints are the first and most important
symptom of MCI
5 and the most obvious expression of the
cognitive impairment.Cognitive impairment can be eas-
ily induced pharmacologically in animals by administer-
ing anticholinergic agents,such as scopolamine.However,
according to Sarter et al,
6 this creates an “indiscriminate”
model,since too many of the drugs tested on it gave pos-
itive results,but then failed to pass further,more specific
testing. Other pharmacological models of memory
impairment can be created by blocking the glutamate N-
methyl-D-aspartate (NMDA)–type receptors,
7 and by
administering benzodiazepines.
8 However,the animals
showing drug-induced memory impairment cannot be
considered to be models of MCI,as they only show one
of the features listed in Table I,ie,memory impairment.
For this reason,they will not be discussed further in this
review.They are,however,useful tools in the investiga-
tion of cognitive mechanisms and their neurotransmitter
systems,and for rapid and inexpensive screening of new
molecules that are potentially active on cognitive deficits.
Animals with cognitive impairment resulting from lesions
in the forebrain cholinergic system,induced by neuro-
toxin administration,will not be included in this overview
either, since they are considered a model of AD,
9 and
their deficit in learning and memory is often too severe.
10
The animal models described above will be examined in
detail in the following sections.
Aging rats
Aging rats have been used extensively for investigating
age-dependent memory impairment,and the underlying
neurochemical changes,and for studying drugs that are
potentially active on the aging process.Out of the exten-
sive literature on the learning and memory impairment
in aging rats,we can select studies comparing the cogni-
tive behavior of rats of different ages (young, middle-
aged,and old) and those in which middle-aged rats were
used.After analyzing the collected data,an attempt has
been made, in the following paragraph, to answer two
questions:(i) to what extent can aging be considered a
model of MCI;and (ii) what is the earliest age at which
a decline in learning and memory can be detected in the
rat? 
In male Wistar rats,Pepeu et al
11 demonstrated that a sta-
tistically significant impairment in the acquisition and
retention of a passive avoidance conditioned response
can be detected at 16 months of age,and the impairment
severity gradually increases in the following months.In
the same rat strain,a statistically significant impairment
in object recognition was detected at 20 to 22 months of
age, using a 60-min intertrial time, while at 16 to 18
months there was only a slight reduction of the discrim-
ination index in comparison with the 3-month-old rats.
12
Selected abbreviations and acronyms
A   -amyloid
AD Alzheimer’s disease
APP amyloid precursor protein
MCI mild cognitive impairment
SHR spontaneously hypertensive rat
Table I. Features that characterize mild cognitive impairment (MCI) ani-
mal models.
Old age 
Subtle memory impairment
Mild neuropathological changes
Changes in the cholinergic system
The above features are associated with:
• Normal motor activity
• Normal feeding behavior
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Thus,it can be assumed that,if the intertrial time is longer,
impairment could also be detected in younger rats.In a
social memory/recognition task in which 3-,15-,and 22-
month-old Fischer-344 rats were exposed to a novel
female stimulus, a significant shortening in the explo-
ration time had already occurred in the 15-month-old
rats, in comparison with the 3-month-old ones, when a
novel female stimulus was introduced, while the 22-
month-old rats failed to investigate the stimulus.
13
Fuchs et al
14 reported that 19-month-old rats from the
Emd:Wi-AF/Han strain showed an impairment in the
acquisition of a one-way avoidance task,but acquired a
two-way avoidance task (shuttle-box) as well as 3-month-
old rats;33-month-old rats showed a marked impairment
in both tasks.Middle-aged (14-month-old) Long-Evans
rats took significantly longer than young (3-month-old)
animals to retrieve their rewards and made significantly
more errors in an eight-arm radial maze paradigm.
15 In the
Morris water maze,a progressive decline in spatial learn-
ing was demonstrated between groups of 3-,12-,18-,24-,
and 30-month-old female Sprague-Dawley rats.If time and
distance covered to find the platform were compared,an
impairment in acquisition appeared in the 24-month-old
rats,and was markedly increased in the 30-month-old rats.
However,if the rats were divided into cognitively impaired
and not impaired groups, using the value of 2 standard
deviations from the mean performance of the 3-month-old
rats as the criterion, 8% of the rats were already cogni-
tively impaired at 12 months and 45% at 18 months of
age.
16 Similarly,50% of female Dark Agouti rats already
showed a learning deficit at 14 months of age,using a com-
plex maze task,and 71% of the rats were impaired at 26
months of age.
17 However,dividing the rats into cognitively
impaired and not impaired groups was too strict a crite-
rion to identify MCI rats,which presumably fall into the
not impaired group.
More subtle criteria are therefore needed.For instance,
by testing Fischer-344 male rats in the Morris water maze,
Lindner et al
18 were able to detect a difference in perfor-
mance,evaluated as distance swam,between 2- and 16-
month-old rats and observed that the aging rats had
more impairment in the reference memory task,which
was tested by keeping the target location in the same
place, but using a longer intertrial interval than in the
working memory task,in which the target location was
changed,but the intertrial interval was short.
Increasing the retention time, ie, the interval between
acquisition and testing,is a simple and effective proce-
dure for unmasking memory deficits in aging rats.In a
non-matching-to-sample task, 15- and 24-month-old
Sprague-Dawley rats did not show any deficit if the delay
between the sample and choice responses was 0 s,but an
impairment was revealed when variable 0 to 24 s delay
intervals were introduced.
19 By increasing the delay,
memory impairment was detected in 17-month-old rats
performing a delayed alternation task.
20
Fourteen months is also the age at which a decline in
memory ability,tested by an allocentric place determi-
nation task in a water maze,
21 was detected in Fisher-344
rats, individually followed throughout their life, as a
decrease in accuracy.The decline progressed with age
and could be reversed by inhibiting cholinesterase with
physostigmine at the age of 22 to 23 months,but not at
26 to 27 months.An improvement in spatial learning was
reported in navigation in a water maze,evaluated as time
required to reach the platform,in 20-month-old Lister
hooded rats receiving 40 to 80 mg/day aspirin in their
drinking water.
22
The above data, some of which are also presented in
Table II for an easier comparison, make it possible to
answer the question regarding the age at which cognitive
impairment can be detected in the rat.It appears that the
possibility of detecting an initial cognitive impairment in
animals, mimicking MCI in humans, depends on many
factors:the task that the animals are trained to acquire,
the procedure used to train them to meet the criterion,
the strain, and, most importantly, the interval between
acquisition and recall.Environmental influences also play
a role,as demonstrated by the finding that Long-Evans
aging rats kept in an enriched environment made fewer
errors in a maze than rats of the same age kept in an
impoverished environment.
23
With appropriate tests,a deficit can be detected early on,
starting from 14 months of age.Fisher-344 rats show cog-
nitive impairment slightly earlier than other strains,but
by 16 to 18 months of age some subtle deficits can be
observed in both sexes of most strains.The strain differ-
ences in water maze acquisition and recall were exten-
sively investigated by Wyss et al
24 comparing Sprague-
Dawley,Wistar-Kyoto,and spontaneously hypertensive
rats (SHRs) in the Morris water maze paradigm.
Sprague-Dawley rats showed that spatial learning began
to decline between 12 and 18 months of age and fell off
precipitously between 18 and 24 months of age. Both
Wistar-Kyoto and SHR strains already showed impair-
ment at 12 months of age.Basic research
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In 14- to 19-month-old rats, many of the features that
should characterize the MCI animal model, listed in
Table I,are present:first,by definition,old age,then the
subtle memory impairment and mild neuropathological
changes. Among the latter, astrogliosis has been
described in aging Wistar rats,
25 a loss of cholinergic neu-
rons has already been observed in cognitively impaired
rats at 14 months of age,
18 and a large decrease in acetyl-
choline (ACh) release from the cerebral cortex, hip-
pocampus,and striatum has been reported in 19-month-
old Wistar rats.
26 Moreover,in the age range of 14 to 19
months,the motor activity and feeding behavior of the
rats are still similar to those of young adult rats.It should
be mentioned that Gallangher
27 explicitly considers age-
related cognitive decline in rats as a “naturally occurring
animal model of MCI.”
Aging rats have been widely used for testing drugs
potentially useful for treating memory deficits and senile
dementia. A few examples of drug-induced memory
improvement,taken from the author’s experience,will be
mentioned.A recovery of age-associated impairment in
the acquisition of a passive avoidance response was
observed in 18-month-old rats treated with phos-
phatidylserine intraperitoneally (IP) for 7 days.
28 Nerve
growth factor (NGF),administered intracerebroventric-
ularly (ICV) for 14 days, restored age-impaired object
recognition in 20-month-old rats.
29A single administra-
tion of aniracetam was able to restore object recognition
in 22-month-old rats.
12 Drugs aimed to facilitate learning
may have no effect in young rats,but improve the per-
formance in aging rats and the size of the improvement
is,to some extent,proportional to the severity of cogni-
tive impairment.For instance,the effect of the ampakine
BDP-12
15 in restoring retention to the level of young rats
was larger in middle-aged rats with minimal experience
in the maze than in those with extensive maze experi-
ence.The α2-adrenoceptor agonist medetomidine,tested
on a delayed alternation task,exerted no effect in young
rats, a small effect at 7 to 11 months, and significant
improvement in performance at 17 to 18 months of age.
20
On the other hand, according to Takefumi et al,
21
physostigmine ameliorated the performance of a place
navigation task in 22- to 23-month-old rats, but lost its
effect in 26- to 27-month-old rats.
To conclude this section,the “middle-aged rat”appears
to be a useful and convenient model for MCI,but with
the caveat that the therapeutic efficacy of very few of the
many candidate drugs tested on this model was later con-
firmed beyond doubt in clinical trials. Therefore, the
model may generate “false-positive”drugs,ie,drugs very
active in the animal tests,but with limited or no clinical
efficacy.
Rats with cerebrovascular pathology
The correlation between hypertension and memory
impairment is well known
30 and has been repeatedly con-
firmed.
31,32 Moreover,MCI may be present in the initial
stages of cerebrovascular diseases.
1,33
SHRs are considered a model of human hypertension
and cardiovascular disease.In these animals,a learning
impairment,expressed as more days needed to reach cri-
terion and more errors made,can be observed in a radial
maze test at 12 months of age,earlier than in normoten-
sive rats of the same strain
34,35 and other strains at the
same age.
24 Less efficient learning, demonstrated by
longer latencies in finding the hidden platform,with nor-
mal swim speed,was observed by comparing SHRs with
normotensive Wistar-Kyoto rats.
36 The longer time
needed for learning
34 and remembering
36 observed in the
Table II. Age at which a cognitive impairment can be detected in the rat according to the different behavioral tests used.
Strain Age (months) Behavioral test Reference
Wistar 16 Passive avoidance 7
Emd:Wi-AF/Han 19 One-way active avoidance 11
Wistar 16-18 Object recognition 12
Fischer-344 15 Social memory/recognition 13
Long-Evans 24 Morris water maze 14
Long-Evans 14 Eight-arm radial maze 15
Fischer-344 16 Morris water maze 16
Sprague-Dawley 15 Delayed non-matching-to-sample task 19
Fisher-344 14 Water maze–allocentric place determination 21
Wistar 17 Delayed  alternation 20Animal models of mild cognitive impairment - Pepeu Dialogues in Clinical Neuroscience - Vol 6 . No.4 . 2004
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SHR model is reminiscent of the slowing in cognitive
performance, accompanied by relatively mild impair-
ments of memory, that characterize vascular cognitive
impairment in humans.
37
SHRs show hypertensive brain damage including
astrogliosis, cytoskeletal breakdown, and hippocampal
atrophy at an early age,
38 and subtle cholinergic deficits.
35,36
Long-term treatment with angiotensin-converting enzyme
(ACE) inhibitors lowers blood pressure and prevents 
the cognitive impairment.
39 However,the cognitive impair-
ment in SHRs can also be improved by cognition
enhancer agents,such as oxiracetam.
40
In conclusion,SHRs show mild cognitive deficits and lim-
ited neuropathological lesions,including some damage
to the cholinergic system.Therefore,they mimic the ini-
tial phases of the vascular cognitive impairment,which
may stabilize or progress toward vascular dementia with
much severer cognitive impairments.Models of this pro-
gression to vascular dementia, could include transient
cerebral ischemia,
41 bilateral middle artery occlusion,
42
and global cerebral ischemia,
43 which all induce extensive
neuropathological changes associated with severe cogni-
tive impairment.
Aging and transgenic mice
For a long time,mice have been less popular than rats for
studying brain aging, mainly because much less neu-
roanatomical and neurochemical information was avail-
able on mice than on rats.In recent years,the generation
of many types of transgenic mice,including those over-
expressing amyloid precursor protein (APP), have
brought mice to the forefront of aging research since they
present extensive Aβ deposition and can be considered
an animal model of AD.
Dean et al
44 studied age-related behavioral differences in
the C57BL mouse and observed that, in the passive
avoidance test,the number of mice failing to avoid the
dark chamber in which the mice had previously been
shocked is higher at 9 than at 3 months of age.Similarly,
10-month-old mice need a higher number of trials to cri-
terion in a T-maze task than the 3-month-old mice.The
cognitive impairment revealed by these tests becomes
progressively more severe at 23 and 31 months of age.
Impairment in the acquisition and retention of the water
maze task was detected in 18- to 19-month-old C57BL
mice and was associated with a decrease in the volume
of the septal cholinergic neurons.
45
It has already been mentioned that MCI can be consid-
ered to be a transitional state between normal aging and
dementia.Since transgenic mice presenting Aβ deposits
are considered to be a model of AD,it should be possi-
ble to detect a prodromal phase of the disease with the
features of MCI.The learning deficit related to age and
Aβ plaques was investigated by Chen et al
46 in PDAPP
transgenic mice and nontransgenic mice of different ages.
Age did not affect the object recognition test in trans-
genic or wild-type mice.Conversely,in the Morris maze
test,an age-related impairment of spatial memory was
evident in both groups of mice,but was clearly more pro-
found in the transgenic mice, and a relationship was
found between the Aβ plaque burden and learning
impairment. However, only in the group of young (9
months) transgenic mice was it possible to detect an
impairment in learning the first platform location that
was associated with a minimal plaque burden and could
reasonably be considered as MCI.Retardation in initial
learning and in learning a new escape location had also
been previously observed
47 in transgenic mice for
APP695 in which no amyloid deposition was detected.In
contrast to these results,Westerman et al
48 demonstrated
that,in Tg 2576 mice overexpressing human APP695 with
the “Swedish” mutation, spatial memory impairment,
evaluated in the Morris water maze,could be detected
beginning from the age of 6 to 11 months and coincided
with the appearance of the insoluble form of Aβ.In test-
ing a similar strain in a passive avoidance task, it was
demonstrated
49 that, in the transgenic mice, memory
impairment appeared at about 8 months of age and pro-
gressed with aging.At 8 months, there were few senile
plaques and an initial decrease in ACh content in several
brain regions including the cortex and the hippocampus.
The present analysis was confined to the relatively few
papers in which memory and learning were investigated
in transgenic mice in the early stages of the disease devel-
opment,omitting the large number of papers in which old
mice with a marked cognitive impairment and extensive
neuropathology were used. We believe that transgenic
mice overexpressing mutated human APP, in an early
stage,around 8 to 10 months of age,and showing an initial
cognitive impairment,few Aβ deposits,and some cholin-
ergic deficit could be considered a model of MCI.These
mice have been used for testing treatments,such as vac-
cination,aiming to prevent Aβ deposition and subsequent
memory loss.
50,51A 7-month treatment with cholinesterase
inhibitors reduced neither Aβ deposition nor memoryimpairment.
52 Conversely,in 6-month-old Tg 2576 mice,a
6-month treatment with Ginkgo biloba did not prevent the
plaque deposition and protein oxidation,but reduced the
spatial memory impairment.
53These papers demonstrate
that transgenic mice overexpressing Aβ may be useful
models for testing drugs potentially active in preventing
or delaying the conversion from MCI to AD.
Aging monkeys
Monkeys of different species have been widely used for
studying the effect of age on memory,beginning from the
classic papers by Bartus et al.
54,55A review comparing the
memory changes occurring in normal aging in humans,
nonhuman primates,and rats was published in 2003 by
Erickson and Barnes.
56 Given the similarities in cognitive
aging between human and nonhuman primates, MCI
should also occur in the latter.However,in most papers
in which the age-associated changes in cognitive
processes have been investigated in monkeys,only two
groups of monkeys, young and old, were compared. In
rhesus monkeys,the species that is most commonly used,
the age of “young” animals ranges between 3 and 10
years and that of the “old” between 23 and 30 years.
Within the latter age range,memory impaired and unim-
paired monkeys can be recognized,
57 but impairment also
depends on the task that the animals are required to per-
form.For instance,
58 aged monkeys were impaired in a
delayed response test of visuospatial memory when the
retention interval of the task was increased from 0 to 10 s.
When trained in a delayed non-matching-to-sample test
of visual object recognition memory, the aged animals
took longer to learn the task, but were only minimally
impaired if recognition memory was tested at retention
intervals ranging from 10 s to 22 h. In contrast to their
relatively intact performance in the object recognition
task,the same monkeys were dramatically impaired in a
second version of the test that required subjects to
remember the temporal order in which objects were pre-
sented.In a comparison of four groups of monkeys aged
3 to 6, 14 to 17, 20 to 24, and 26 to 30 years,
59 the only
behavioral deficit in the 14- to 17-year-old group was
detected using a difficult visuospatial orientation task.
Impairment in the delayed response task with long delay,
assessing spatial memory,appeared in the 20- to 24-year-
old monkeys,while object recognition was still preserved
and was only impaired in the oldest group.
From the above experiments,it appears that MCI can be
detected in middle-aged monkeys,presumably about 15
years old,if difficult visuospatial tasks are presented to
them. Conversely, since in old monkeys the cognitive
processes are usually well preserved, we can induce a
MCI by a moderate increase in delay in the delayed non-
matching-to-sample task or the delayed response spatial
memory task.However,paradoxically,it could be claimed
that since old monkeys never show the catastrophic loss
of memory,massive degeneration of the cholinergic sys-
tem, and extensive Aβ plaque deposition occurring in
AD,the memory impairment in the aging monkey could
be considered a model of MCI.
The cognitive deficit in the old monkeys can be
improved,with individual marked differences,by drug
treatments.Among the drugs tested are cholinesterase
inhibitors,
60,61 arginine vasopressin,
62 dopamine D1 ago-
nists,
63 adrenergic agonists,
64 and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate (AMPA) receptor allo-
steric modulators.
65 However,like in the rat,few drugs
shown to improve cognition in aging monkeys have
become useful therapeutic agents in man.
Conclusions
This survey of the literature on aging in laboratory ani-
mals reveals that there are several possible models of
MCI.If they are listed according to cost and availability,
their order of preference would be middle-aged rats and
mice, transgenic mice overexpressing Aβ, at an early
phase before extensive deposit formation, and aging
monkeys. SHRs are a model of MCI that occurrs in
hypertensive patients.Strain differences are not relevant
while the selection of the behavioral task is very impor-
tant for detecting the cognitive deficit at an early age.
Although the animal models described in this review
have frequently been used to test potentially useful drugs
for the treatment of the memory deficits, which is the
main symptom of MCI, a validation of the models
through comparable therapeutic results in both animal
and man has been rarely obtained. ❏
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Deterioro cognitivo leve: modelos animales
El deterioro cognitivo leve (DCL) es parte del enve-
jecimiento cognitivo y se considera un estado de
transición entre el envejecimiento normal y la
demencia, en la cual se puede convertir. Para una
comprensión de los mecanismos patogénicos del
DCL y para el desarrollo de fármacos para su trata-
miento se requieren modelos animales apropiados.
En esta revisión se identifican las características que
debe tener un modelo animal de DCL, como edad
avanzada, deterioro discreto de la memoria, cam-
bios neuropatológicos leves y cambios en el sistema
colinérgico, y también la edad en la cual estas carac-
terísticas se pueden detectar en los animales de
laboratorio. Estas características deben presentarse
en animales viejos con actividad motora y conducta
alimentaria normales. Los modelos animales pue-
den ser ratas y ratones de edad media, ratas con
isquemia cerebral, ratones transgénicos con sobre-
expresión de proteína precursora de amiloide y pre-
senilina 1 (evaluadas en una etapa precoz) o monos
viejos. Los déficits de memoria pueden ser detecta-
dos seleccionando pruebas conductuales adecua-
damente difíciles, y los déficits se pueden asociar
con alteraciones neuropatológicas. La literatura
revisada demuestra que bajo ciertas condiciones
estas especies animales pueden ser consideradas
modelos de DCL, y el deterioro cognitivo en estos
modelos responde al tratamiento con fármacos.
Déficit cognitif léger : modèles animaux
Le déficit cognitif léger (Mild Cognitive Impairment,
MCI) est un aspect du vieillissement cognitif consi-
déré comme un état de transition entre le vieillis-
sement normal et la démence vers laquelle il peut
évoluer. Des modèles animaux appropriés sont
nécessaires afin de comprendre les mécanismes pa-
thogènes du MCI et de développer les médicaments
qui le traiteront. Dans cet article, nous identifions
les critères qui devraient caractériser un modèle ani-
mal de MCI, à savoir un âge avancé, un déficit mné-
sique discret, des modifications neuropathologiques
légères et des modifications du système cholinergi-
que, et l’âge auquel il est possible de détecter ces
caractéristiques chez les animaux de laboratoire.
Elles devraient apparaître chez des animaux vieil-
lissants avec une activité motrice et un comporte-
ment alimentaire normaux. Les modèles animaux
peuvent être des rats et des souris d’âge moyen, des
rats avec une ischémie cérébrale, des souris trans-
géniques dont la préséniline 1 (testée à un stade
précoce) et la protéine précurseur amyloïde sont
surexprimées, ou des singes vieillissants. Il est pos-
sible de détecter les déficits mnésiques en sélec-
tionnant judicieusement des tâches comportemen-
tales difficiles et de retrouver une association avec
des altérations neuropathologiques. Une revue de
la littérature montre que, sous certaines conditions,
ces espèces animales peuvent être considérées
comme des modèles de MCI et que le déficit cogni-
tif répond au traitement médicamenteux dans ces
modèles.
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